ML20199A229: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot insert)
 
(StriderTol Bot change)
 
Line 13: Line 13:
| document type = CORRESPONDENCE-LETTERS, OUTGOING CORRESPONDENCE
| document type = CORRESPONDENCE-LETTERS, OUTGOING CORRESPONDENCE
| page count = 2
| page count = 2
| project = TAC:L30995
| stage = RAI
}}
}}



Latest revision as of 06:40, 8 December 2021

Forwards RAI Re Amend Application,Dtd 970812,requesting Authorization for Release of Hydrofluoric Acid for Unrestricted Use
ML20199A229
Person / Time
Site: 07000036
Issue date: 11/06/1997
From: Soong S
NRC OFFICE OF NUCLEAR MATERIAL SAFETY & SAFEGUARDS (NMSS)
To: Sharkey R
ABB COMBUSTION ENGINEERING NUCLEAR FUEL (FORMERLY
References
TAC-L30995, NUDOCS 9711170109
Download: ML20199A229 (2)


Text

- - -

' ' Mr. Robert W. Sharkey. Manager November 6, 1997 l

Lf

-Regulatory Compliance Combustion Engineering. Inc.

3300 State Road P.

Hematite.- M0 63047

$UBJECT: AMENDMENT REQUEST FOR UNRESTRICTED RELEASE OF HYDROFLUORIC ACID (TAC NO. L30995)

Dear Mr. Sharkey:

, This refers to your application dated August 12. 1997. requesting-an amendment to Materials License SNM 33 to authorize release of hydrofluoric acid for unrestricted use.

Our review of your application has identified additional information that is needed before final action can be taken on your request. The additional information, specified in the enclosure, should be provided within 30 days of the date'of this letter. Please reference the above TAC No, in future correspondence related to this request.

If you have any questions regarding this matter, please contact me at (301) 415-8155.

Sincerely.

Sean Soong Licensing Section 2 ,

Licensing Branch 7 Division of Fuel Cycle Safety N and Safeguards. NMSS

)

I Docket 70-36 License SNM-33 b."$ k!E @ijJ$ Q,p1.1 i Enclosurei As-stated Distribution: w/ encl. (Control No. 700S) [ PARTIAL)

Docket 70-36 PUBl.IC .NRC File Center FCSS R/F Region III FCLB R/F TReidinger. RIII NMSS R/F

[c:\chotoo\ hematite \hf. rail 0FC.- FCLB E FCLB F FCLB h FCLB A/

NAME Schotoo-efd - SSoong fy PSD.a- 3d MATJ)Why 11/[;'/97 DATE 11/ (o /97 11//, -/97 11/ lo /97

.9711170109 971106T ,

L-. ~,

4

. Request for Additional Information Application Dated August 12, 1997 i Combustion Engineering, Inc.

Docket 70 36

1. Is there a possibility that the uranium released in the hydrofluoric acid (HF) may be reconcentrated (for example. in a waste treatment or metal recovery operation after use of the HF)? Provide a conservative dose assessment for this possibility, considering not only the original buyer but possible end uses of the material.
2. Commit to representative sampling of the hold tank before release of carb batch of HF.
3. You indicated in your August 12. 1997, submittal that a diked pad will be constructed for the HF holding tank. What volume of HF will the diked area be capable of containing in the event of a leak? Justify why this volume is sufficient.
4. Indicate the total volume of HF per year Vnich is expected to be transferred from the site for unrestricted use.
5. Correct the dose unit in the third column of Table 2 of your August 12.

1997. submittal.

6. Provide the basis for the internal dose estimates used to calculate he total effective dose equivalent presented on page 9 of your August 12.

1997, submittal. The internal doses cited are lnconsistent with the calculations presented on pages 6 and 7 of your submittal ENCLOSURE

- _ . _ _ . - . . . _ _ _ _ . ~ _ . . _ . _ . . _ _ _ . _ _ . . _ _ _ _ _ _ .

y '

November 6, 1997 T.

  • LMr LRobertW;Shnkey, Manager

+ Regulatory Compliance 1 Combustion Engineering; Inc. _

3300 State Road P '

Aematite,'MO63047-

SUBJECT:

- 'AMLNDMENT;REQUESTFORUNRESTRICTEDRELEASEOFHYDROFLOORICIACID

.(TAC NO. L30995) ,

t p

L

Dear Mr. Sharkey:

This refers to your application dated August 12, 1997, requesting an amendment to Materials License SNM-33 to authorize release of hydrofluoric acid for unrestricted use, ,

Our review of your application has identified additional information that'is needed before final action can be taken on your request. Th'e additional information, specified in the enclosure, shouhl be provided within 30 days of .

-the date of this letter. Please reference-the above TAC No, in future correspondence related to this request.

. If'you have any questions regarding this matter, please contact me at (301)

'415-8155.

Sincerely, Sean Soong Licensing Section 2

- Licensing Branch e Division of Fuel Cycle Safety and Safeguards -NMSS Docket 70-36 License SNM-33

Enclosure:

As stated Distribution: -w/ encl. (Control No; 7005)-[ PARTIAL]

Docket 70-36: PUBLICL NRC' File Center FCSS R/F

-Region III FCLB R/F_ TReidinger. RIII NMSS R/F-

[c:\chotoo\ hematite \hf.rai)'

0FC FCLR E- FCLB g FCLB h FCLB A)

NAME' SchotooJegC- SSoong-9; PShea - M M%y DATE' 11/ (, /97 11/fi /97 _

11/ [ '/97 11/ lo /97 NMN __. _ __ .- _ .._ _ _ _ .

? =

4

~

P.equest for Additional Information Application Dated August 12, 1997 Combustion Engineering, Inc. >

Docket 70 36

1. Is there a possibility that the uranium released in the hydrofluoric acid (HF) may be reconcentrated (for example, in a waste treatment or metal recovery operation after use of the HF)? Provide a conservative dose assessment for tnis possibility, considering not only the original buyer but possible end uses of the materic1.
2. Commit to representetive sampling of the hold tank before , clease of ertl batch of HF.
3. You inalcated in your August 12. 1997, submittal that a diked pad will be constructed for the HF holding tank. What volume of HF will the diked area be capable of containing in the event of a leak? Justify why this volume is suf ficient.
4. Indicate the total volume of HF per year which is expected to be trensierred from the site for unrestricted use.
5. Correct the dose unit in the third column of Table 2 of your August 12.

1997, submittal.

6. Provide the basis for the internal dose estimates used to calculate the total effective dose equivalent presented on page 9 of your August 12.

1997, submittal. The internal doses cited are inconsistent with the calculations presented on pages 6 and 7 of your submittal.

9 ENCLOSURE L -

_ - _ _ _ _ _ _ _ _ _ - _ _ _ _ _ _ _ _